Boundless Bio Inc (BOLD) Actualités

Form 8-K - Current report

Boundless Bio Announces Pipeline and Leadership Updates

Company elects not to advance BBI-825 into Part 2 portion of STARMAP clinical trial Third ecDTx program...

Boundless Bio to Participate in the Piper Sandler Healthcare Conference

SAN DIEGO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Boundless Bio Reports Third Quarter 2024 Financial Results and Business Highlights

Enrollment progressing in BBI-355 POTENTIATE and BBI-825 STARMAP clinical trials, with initial proof-of-concept...

Boundless Bio to Participate in the 2024 Guggenheim Global Healthcare Conference

SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company...

Form 8-K - Current report

Boundless Bio Announces Departure of Chief Financial Officer

SAN DIEGO, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company...

Boundless Bio to Participate in the 2024 Cantor Global Healthcare Conference

SAN DIEGO, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Boundless Bio (Nasdaq: BOLD), a clinical-stage oncology company...

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Boundless Bio Provides Business Updates Focused on Key Value Drivers and Reports Second Quarter 2024 Financial Results

BBI-355 POTENTIATE clinical trial ongoing with initiatives implemented to expedite enrollment in combination...